Is the Cardiff Oncology (CRDF) investment thesis intact?

It is under pressure. Readouts currently rates the Cardiff Oncology Thesis Challenged. Onvansertib follow-up extends; financing remains key to planned Phase 3.

What is the next catalyst for Cardiff Oncology (CRDF)?

The next dated event is Phase 3 start (CRDF-005) for Onvansertib, expected Q1 2027, as stated by the company.

How long will Cardiff Oncology's cash last?

Cardiff Oncology has said its cash will fund operations into Q3 2027 (guidance as of August 11, 2026). It reported $34.5 million in cash as of June 30, 2026.

CRDFCardiff Oncology, Inc.

Market reactionShares fell 13% on Nov 5.

ChallengedLast material event Aug 11, 2026 · Updated Oct 27, 2026

Onvansertib follow-up extends; financing remains key to planned Phase 3

Cardiff Oncology is a clinical-stage company developing onvansertib, an oral PLK1 inhibitor, for first-line RAS-mutated metastatic colorectal cancer; it is not approved.

Cardiff's case rests on oral PLK1 inhibitor onvansertib plus FOLFIRI/bevacizumab in first-line RAS-mutated metastatic colorectal cancer. Randomized Phase 2 response results support development; median PFS remains unreached in the selected 30 mg arm, but comparative PFS remains uncertain. The Nerviano settlement protects development rights. Phase 3 remains planned for the first quarter of 2027, subject to additional financing. Management projects runway into the third quarter of 2027, including the subsequent $10 million offering.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

Cardiff funds the Phase 3 trialAt riskFinancing terms and the portion of the registrational program they can support.Next: Financing terms and the portion of the registrational program they can support.

Why it is in this state

The evidence, what would weaken it and the source filing

Phase 3 starts on the FDA-aligned designAwaiting evidenceFirst patient dosing in the planned randomized registrational trial.Next: First patient dosing in the planned randomized registrational trial.

Why it is in this state

The evidence, what would weaken it and the source filing

Onvansertib rights are secureSupportedConfirmation of litigation dismissal and detail on compliance with the amended development objectives.Next: Confirmation of litigation dismissal and detail on compliance with the amended development objectives.

Why it is in this state

The evidence, what would weaken it and the source filing

Longer follow-up confirms the Phase 2 benefitAwaiting evidenceUpdated comparative PFS for the selected regimen, including confidence intervals and remaining patient counts.Next: Updated comparative PFS for the selected regimen, including confidence intervals and remaining patient counts.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Funding the registrational program

Tests: Cardiff funds the Phase 3 trial

Planned trial initiation: first quarter of 2027, subject to additional financing.

Can Cardiff secure financing to start and sustain its planned registrational trial?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentRegulatory

-5.7%Aug 11, 2026

Onvansertib follow-up extends; financing remains key to planned Phase 3

ChallengedClinical

+10.7%Jun 3, 2026

Onvansertib's Phase 2 ORR signal in RAS-mutated mCRC heads to Phase 3, but runway expires before enrollment completes and a license dispute clouds IP ownership

IntactCommercial

-7.3%Jun 2, 2026

Onvansertib's Phase 2 ORR and PFS signal in first-line RAS-mutated mCRC sets up a Phase 3 bet contingent on financing survival and registrational replication

IntactCorporate

-32.0%Jan 27, 2026

CEO Mark Erlander steps down; Mani Mohindru appointed interim CEO

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Colorectal cancer· first-line RAS-mutated

onvansertib · 1 upcoming · 4 completed

Phase 3 Study InitiationCRDF-005Pivotal

Q1 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Cardiff Oncology (CRDF) investment thesis intact?: It is under pressure. Readouts currently rates the Cardiff Oncology Thesis Challenged. Onvansertib follow-up extends; financing remains key to planned Phase 3.
What is the next catalyst for Cardiff Oncology (CRDF)?: The next dated event is Phase 3 start (CRDF-005) for Onvansertib, expected Q1 2027, as stated by the company.
How long will Cardiff Oncology's cash last?: Cardiff Oncology has said its cash will fund operations into Q3 2027 (guidance as of August 11, 2026). It reported $34.5 million in cash as of June 30, 2026.

Other companies we cover in these diseases

Metastatic colorectal cancer: Delcath Systems (DCTH)Bicycle Therapeutics (BCYC)TransCode Therapeutics (RNAZ)Adagene (ADAG)Coherus Oncology (CHRS)BridgeBio Oncology Therapeutics (BBOT)Context Therapeutics (CNTX)

Disease areas: Blood cancers, Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

12 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.